pharmaphorum

APRIL 20, 2021

The cost-effectiveness agency has said that anti-CD20 antibody Kesimpta (ofatumumab) can be prescribed via the NHS in England and Wales as a treatment for adults with RMS with active disease, as either a first-line therapy or after alternative drugs have been tried. billion by 2028. billion in sales in 2028.

Sales 111

Sales Medicine Drugs Marketing 111

XTalks

MAY 2, 2024

The Prescription Drug User Fee Act (PDUFA) date is the deadline that the FDA sets for reviewing a New Drug Application (NDA) or Biologics License Application (BLA) and making a final decision on marketing approval. The review period is typically ten months after the agency accepts a drug application. It is also entering late into the market.

Drugs 52

Drugs FDA Approval Sales Vaccination 52

Pharmaceutical Technology

APRIL 4, 2023

Adcendo is developing antibody-drug conjugates (ADCs) to treat cancers with few approved therapies. million) in the latest extension round, which was led by Pontifax Venture Capital, and existing investors Novo Holdings and Ysios Capital, along with RA Capital Management, HealthCap and Gilde Healthcare.

Development 130

Development Licensing Licensing Antibody 130